JOURNAL BROWSE
Search
Advanced SearchSearch Tips
The Effects of Hataedock on 2,4-dinitrofluorobenzene Induced Atopic Dermatitis Like Skin Lesion in NC/Nga Mice
facebook(new window)  Pirnt(new window) E-mail(new window) Excel Download
 Title & Authors
The Effects of Hataedock on 2,4-dinitrofluorobenzene Induced Atopic Dermatitis Like Skin Lesion in NC/Nga Mice
Cha, Ho Yeol; Ahn, Sang Hyun; Jeong, A Ram; Cheon, Jin Hong; Park, Sun Young; Kim, Ki Bong;
  PDF(new window)
 Abstract
Objectives Hataedock is the treatment that dispels toxic heat and meconium gathered at the fetus for the new born baby by orally administered herbal extracts. The purpose of this study was to evaluate whether Hataedock alleviate inflammatory skin damages in AD-induced NC/Nga mice through regulating of skin barrier maintain and Th2 differentiation. Methods We established an AD model in the 3-week-old NC/Nga mice through the repeated application of DNFB (dinitrochlorobenzene) on days 28, 35, 42 after Hataedock treatment which was orally administered. We identified the changes of skin barrier and Th2 differentiation through the histological and immunohistochemical changes of protein kinase C (PKC), interleukin (IL)-4, degranulated mast cell, Substance P and MMP-9. Results Our results suggested that Hataedock treatment significantly down-regulated levels of PKC by 82% (p < 0.001), as well as IL-4 by 56% (p < 0.001). Hataedock also suppressed mast cell infiltration, ear edema formation. and Substance P in the tissue of NC/Nga mice were decreased by 57% (p < 0.001), and MMP-9 by 55% (p < 0.001). Conclusions These results suggest that Hataedock alleviates AD through the down-regulation of PKC and Th2 cytokines, which are involved in the initial steps of AD development. Hataedock have potential application for the treatment of AD.
 Keywords
Hataedock;Atopic dermatitis;PKC;IL-4;NC/Nga mouse;DNFB;
 Language
Korean
 Cited by
 References
1.
Korean Dermatological Association Textbook Compilation Committee. Dermatology, 5th. Seoul: Ryo Moon Gak. 2008:170-1.

2.
Blume-Peytavi U, Metz M. Atopic dermatitis in children: management of pruritus. J Eur Acad Dermatol Venereol. 2012;26:2-8.

3.
Addor FA, Takaoka R, Rivitti EA, Aoki V. Atopic dermatitis: correlation between non-damaged skin barrier function and disease activity. Int J Dermatol 2012;51:672-6. crossref(new window)

4.
Kabashima K. New concept of the pathogenesis of atopic dermatitis: Interplay among the barrier, allergy, and pruritus as a trinity. J Invest Dermatol. 2013;70:3-11.

5.
Leung DY. Atopy dermatitis: new insight and opportunities for therapeutic intervention. J Allergy Clin Immunol. 2000;105:860-7. crossref(new window)

6.
Beltrani VS. The role of house dust mites and other aeroallergens in atopic dermatitis. Clin Dermatol. 2003;21(3):177-82. crossref(new window)

7.
Jiangyu R. Practical TCM Pediatrics. Shanghai: Shanghai Science and Technology Press. 2005.

8.
Kang MY, Jang GT, Kim JH. A study on fetal toxicosis removal therapy. J Pediatr Korean Med. 2003;17(1):9-51.

9.
Heo J. DongUiBoGam. 2nd ed. Seoul: NamSanDang. 2004.

10.
Bieber T. Atopic dermatitis. N Engl J Med. 2008;358:1483-94. crossref(new window)

11.
Akdis CA, Akdis M, Bieber T, Bindslev-Jensen C, Boguniewicz M, Eigenmann P, Hamid Q, Kapp A, Leung DY, Lipozencic J, Luger TA, Muraro A, Novak N, Platts-Mills TA, Rosenwasser L, Scheynius A, Simons FE, Spergel J, Turjanmaa K, Wahn U, Weidinger S, Werfel T, Zuberbier T. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/American Academy of Allergy, Asthma and Immunology/ RACTALL Consensus Report. J Allergy Clin Immunol. 2006;118(1):152-69. crossref(new window)

12.
Cork MJ, Danby SG, Vasilopoulos Y, Hadgraft J, Lane ME, Moustafa M, Guy RH, Macgowan AL, Tazi-Ahnini R, Ward SJ. Epidermal barrier dysfunction in atopic dermatitis. J Invest Dermatol. 2009;129(8):1892-908. crossref(new window)

13.
Ye YM, Kim BE, Shin YS, Park HS, Leung DYM. Overexpression of epidermal filaggrin in patients with chronic idiopathic urticaria correlates with urticaria severity. J Allergy Clin Immunol. 2013;131(2):AB56.

14.
Sandstrom MH, Faergemann J. Prognosis and prognostic factors in adult patient with atopic dermatitis : a long-term follow-up qeustionnaire study. Br J Dermatol. 2004;150:103-10. crossref(new window)

15.
Dupuy P. Does atopic dermatitis result from cytokine dysregulation?. J invest Dermatol. 1994;92:44-7.

16.
Kim JW. Allergy and immunological perspective in atopic dermatitis. J Korean Dermatol Assoc. 2003;41(6): 687-9.

17.
Ahn PS, Bang HD, Jung JH, Kim GH, Park KC, Yoon JI. Effect of recombinant interferon gamma on the treatment of atopic dermatitis. J Immunol. 1996;16(3):291-8. crossref(new window)

18.
Sung HC, Lee WJ, Lee SJ, Kim DW. A study on the relationship of allergy-related labaratory findings with the clinical severity of atopic dermatitis. J Korean Dermatol Assoc. 2006;44(9):1051-7.

19.
Sidbury R, Hanifin JM. Old, new, and emerging therapies for atopic dermatitis. Dermatolo Clin. 2000;18(1):1-11.

20.
Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today. 1992;13(4):136-42. crossref(new window)

21.
Kim SH, Kim S, Lee SH, Park HW, Chang YS, Min KU, Cho SH. The effects of PG102, a water-soluble extract from actinidia arguta, on serum total IgE levels:a double-blind, randomized, placebo-controlled exploratory clinical study. Eur J Nutr. 2011;50(7):523-9. crossref(new window)

22.
Kim D, Kim SH, Park EJ, Kang CY, Cho SH, Kim S. Anti-allergic effects of PG102, a water-soluble extract prepared from actinidia arguta, in a murine ovalbumin-induced asthma model. Clin Exp Allergy. 2009;39(2):280-9. crossref(new window)

23.
Jo JJ. Gup Yu Bang. Seoul: Yeo kang publishing company. 1998:44.

24.
Jeong JM. A study regarding current usage of Ha-Taedok method in korean pediatrician. J Pediatr Korean Med. 2014;28(2):88-102. crossref(new window)

25.
Jeong JM. A study regarding current usage of Ha-Taedok method in postpartum mothers. J Pediatr Korean Med. 2014;28(4):157-65. crossref(new window)

26.
Yu JG, Yuan RJ. Rhubarb and licorice tang in use in neonatal diseases. Henan Medical Information. 2008; 6(8):46-7.

27.
Korea Centers for Disease Control and Prevention. Childhood asthma and allergic diseases cohort study, 4th study 2012. Retrieved on April 24, 2013 from http: / /www.cdc.go.kr/CDC/ info/CdcKrInfo0 201 jsp?menuIds=HOME001-MNU1155-MNU1083- MNU1375-MNU0025&cid=21510.

28.
Korean Medical Pharmacology Text publication committee. Korean medical pharmacology. Seoul: Shinil Books. 2010:116-249.

29.
Moon A, Kim SH. Effect of Glycyrrhiza glabra roots and glycyrrhizin on the glucuronidation in rats. Planta Med. 1997;63:115-9. crossref(new window)

30.
Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986;136(7):2348-57.

31.
Miraglia del Giudice M, Decimo F, Leonardi S, Maioello N, Amelio R, Capasso A, Capristo C, Capristo AF. Immune dysregulation in atopic dermatitis. Allergy Asthma Proc. 2006;27(6):451-5.

32.
Antunez C, Torres MJ, Mayorga C, Corzo JL, Jurado A, Santamaria-Babi LF, Vera A, Blanca M. Cytokine production, activation marker, and skin homing receptor in children with atopic dermatitis and bronchial asthma. Pediatr Allergy Immunol. 2006;17(3):166-74. crossref(new window)

33.
Lee HH. Atopic Dermatitis and Epidermal Barrier. Allergy Asthma & Respiratory Disease. 2009;19(2):95-105.

34.
Connelly L, Palacios-Callender M, Ameixa C, Moncada S, Hobbs AJ. Biphasic regulation of NF-kappa B activity underlies the pro- and anti-inflammatory actions of nitric oxide. J Immunol. 2001;166(6):3873-81. crossref(new window)

35.
Chen L, Grabowski KA, Xin JP, Coleman J, Huang Z, Espiritu B, Alkan S, Xie HB, Zhu Y, White FA, Clancy J Jr, Huang H. IL-4 induces differentiation and expansion of Th2 cytokine-producing eosinophils. J Immunol. 2004;172(4):2059-66. crossref(new window)

36.
Marsland BJ, Soos TJ, Späth G, Littman DR, Kopf M. Protein kinase C theta is critical for the development of in vivo T helper (Th)2 cell but not Th1 cell responses. J Exp Med. 2004;200(2):181-9. crossref(new window)

37.
Amin K. The role of mast cells in allergic inflammation. Respir Med. 2012;106(1):9-14. crossref(new window)

38.
Park SW, Yan YP, Satriotomo I, Vemuganti R, Dempsey RJ. Substance P is a promoter of adult neural progenitor cell proliferation under normal and ischemic conditions. J Neurosurg. 2007;107(3):593-9. crossref(new window)

39.
Donkin JJ, Turner RJ, Hassan I, Vink R. Substance P in traumatic brain injury. Prog Brain Res. 2007;161:97-109. crossref(new window)

40.
Ebner K, Singewald N. The role of substance P in stress and anxiety responses. Amino Acids. 2006;31(3): 251-72. crossref(new window)

41.
Yamaoka J, Kawana S. Rapid changes in substance P signaling and neutral endopeptidase induced by skin-scratching stimulation in mice. J Dermatol Sci. 2007;48(2):123-32. crossref(new window)

42.
Hon KL, Lam MC, Wong KY, Leung TF, Ng PC. Pathophysiology of nocturnal scratching in childhood atopic dermatitis: the role of brain-derived neurotrophic factor and substance P. Br J Dermatol. 2007;157(5):922-5. crossref(new window)

43.
Toyoda M, Nakamura M, Makino T, Hino T, Kagoura M, Morohashi M. Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol. 2002;147(1):71-9. crossref(new window)

44.
Woessner JF Jr. MMPs and TIMPs-an historical perspective. Mol Biotechnol. 2002;22(1):33-49. crossref(new window)

45.
Burrage PS, Mix KS, Brinckerhoff CE. Matrix metalloproteinases; role in arthritis. Front Biosci. 2006;1:529 -43.

46.
Onodera S, Kaneda K, Mizue Y, Koyama Y, Fujinaga M, Nishihira J. Macrophage migration inhibitory factor up-regulates expression of matrix metalloproteinases in synovial fibroblast of rheumatoid arthritis. J Biol Chem. 2000;275(1):444-50. crossref(new window)